The objective of this study was to assess the effects of omega-3 fatty acid supplementation on various kidney transplantrelated outcomes. A systematic review and meta-analysis was performed of published randomized, controlled trials (RCT). There were 16 kidney transplant RCT with a total of 812 patients. All trials evaluated fish oil with dosages that ranged from 1.2 to 5.4 g/d. No consistent benefits were observed for any outcome with the exception of a modest benefit on triglycerides. A meta-analysis of rejection episodes found no significant benefit on either early (<6 mo posttransplantation) or late episodes. The overall relative risk of having at least one rejection episode in those who received fish oil was 0.91 (95% confidence interval 0.74 to 1.10) in four studies with a follow-up of 1 yr. A meta-analysis of eight RCT of graft survival found no significant benefit (relative risk 1.00, 95% confidence interval 0.96 to 1.05). The available data (mostly derived from older studies with important methodologic limitations) do not demonstrate a consistent, clinically important benefit of fish oil in kidney transplantation.
O mega-3 fatty acids (eicosapentaenoic acid [EPA] , docosahexaenoic acid [DHA] , and ␣ linolenic acid [ALA] ) have a role in mediating inflammation, the immune responses, and lipoprotein metabolism (1) (2) (3) (4) . A variety of health benefits have been attributed to dietary supplementation with omega-3 fatty acids in transplant and nontransplant settings. Several studies in renal transplantation have suggested that supplementation with omega-3 fatty acids (mostly fish oil) may lead to important clinical benefits, such as decreasing cyclosporine (CsA) nephrotoxicity, rejection episodes, and hypertension, while improving hyperlipidemia (5) (6) (7) . However, the magnitude of benefits has been variable, and discordant data have also been published (8, 9) . As a result, their role remains controversial, and they are not used routinely. Whether characteristics of the individual studies could account for the heterogeneous results, thereby possibly revealing a benefit under certain circumstances, is unclear.
To clarify these issues, the Agency for Healthcare Research and Quality (AHRQ), on behalf of the Office of Dietary Supplements at the National Institutes of Health, requested a detailed evaluation of the benefits of omega-3 fatty acid supplementation in all forms of transplantation. This resulted in a detailed systematic review and meta-analysis, produced by the Tufts-New England Medical Center Evidence-based Practice Center, the full text of which is available through the AHRQ web site (www.AHRQ.gov). By far the greatest experience was in kidney transplantation. Thus, this report summarizes the major findings in studies on the effects of omega-3 fatty acid supplementation on kidney transplantation.
Materials and Methods
We searched MEDLINE and MEDLINE In Process and Other NonIndexed Citations (1966 ( to December 2003 , EMBASE (1989 EMBASE ( to 2003 , Biologic Abstracts and Commonwealth Agricultural Bureau databases (1973 to December 2003), BIOSIS abstracts, and Central Cochrane Database of Systematic Reviews (Update Software, issue 4, 2003) for relevant studies. Bibliographies of retrieved citations were also reviewed for additional studies. Members of a Technical Expert Panel, authors of major controlled trials, and experts in kidney transplantation were contacted to identify other sources of data, including unpublished studies.
We included randomized, controlled trials (RCT) without any restriction in sample size and language when they reported any outcome in adults or children who underwent kidney transplantation and received omega-3 fatty acids. Studies were excluded when they focused on nonhuman subjects or were articles without primary sources of data, focused on subjects who did not undergo kidney transplantation, or did not use omega-3 fatty acids or when their amount could not be quantified.
Acceptable sources of omega-3 fatty acids included fish oil (EPA and DHA), vegetable oils that contain ALA (canola, rapeseed, soybean, flaxseed, linseed, walnut, and mustard seed), Mediterranean diet, or other sources in which the quantity was reported explicitly. Pharmaceutical companies and individuals in relevant countries were contacted when a brand name of a supplement lacked a quantitative description of its components.
Major outcomes included the posttransplantation GFR, BP, lipid profile, patient and graft survival, episodes of rejection, and dose and trough levels of CsA. Multiple methods were used to report renal function after transplantation. Direct measurement of the GFR with a radioisotope or inulin was considered to provide the best estimate of renal function compared with indirect methods (e.g., the calculated GFR) or serologic markers such as the plasma concentration of urea nitrogen or creatinine (10) . Direct measurements of GFR or creatinine clearance were used for comparison across studies whenever available.
Important covariates and study characteristics were also recorded. These included, for example, the doses and types of immunosuppressant medications, specific time relative to the transplant that supplementation was introduced, duration of follow-up, and concomitant use of antihypertensive medications and lipid-lowering agents, all of which may have an influence on the major outcomes of interest.
We extracted the following study features: Study design, blinding, randomization method, allocation concealment method, country, funding source, duration, quantity and type of omega-3 fatty acids, eligibility criteria, control interventions, sample characteristics (and their comparability), reasons for withdrawals, and all reported outcomes.
Three authors independently reviewed the full text of studies. Duplicate reports were included when they provided additional data; however, subjects were included and accounted for only once. Two authors compared the triplicate data extraction forms. Discrepancies were resolved by discussion until consensus was achieved.
Statistical Analyses
For continuous outcomes such as BP, GFR, and lipid levels, we described three sets of data: The mean baseline level in the omega-3 fatty acid arm, the net change of the outcome, and the reported P values of the difference between the omega-3 fatty acid and the control arms. The net change is the difference between the change in the omega-3 fatty acid arm and the change in the control arm: Net change ϭ (omega-3 Final Ϫ omega-3 Initial ) Ϫ (control Final Ϫ control Initial ).
When the SE of a change in the omega-3 fatty acid arm or a change in the control arm was not reported, we estimated the SE using a correlation coefficient of 0.5 (11) . To maintain consistency across studies, we calculated the unadjusted net change using the above formula for all studies when the data were available. We included only the reported P values for the net differences. When necessary, we used the 95% confidence interval (CI) or SE of the net difference to determine significance.
For dichotomous or categorical variables, the rates in the treatment and control groups were expressed as a relative risk (RR) and 95% CI. We performed meta-analyses using a random-effects model (12) when there were sufficient clinically comparable data on graft or patient survival and rejection episodes.
For rejection episodes, calculations were performed with the patient (not the rejection episode) as the unit of analysis (because individual patients could have had more than one rejection episode). Thus, the proportion of patients who had a rejection episode at various time points (rather than the total number of rejection episodes) was compared across treatment groups.
Results

Eligible Studies
The literature search identified 1281 abstracts. From these and from the articles found in bibliographies, a total of 78 studies were ultimately selected for full-text review. Forty-nine of these were rejected because they did not fulfill inclusion criteria, and eight studies were excluded as duplicate reports of the same patients, leaving a total of 21 independent RCT on several forms of transplantation. Among these 21 RCT, there were 16 trials on kidney transplantation with a total of 812 patients (Figure 1 ). Fish oil supplements were used in all kidney transplantation studies. The dose of fish oil ranged from 1.2 to 5.4 g/d ( Table 1) .
Quality of Eligible Studies
Studies generally were small, and many had important methodologic limitations. Masking and methods of randomization were generally not well described. Even when masking of patients and caregivers was described, it is likely that they became unmasked because fish oil supplementation was frequently associated with a fishy taste and dyspeptic side effects in the active intervention arm, especially early in the course of treatment. Many trials did not use isocaloric treatments or fats with comparable fatty-acid profiles in the control group, potentially biasing comparisons, especially for cardiovascular out- RCT, randomized, controlled trials; CsA, cyclosporine; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; ARE, acute rejection episode; IS, immunosuppression; C, cadaver donor; L, living donor; Aza, azathioprine; N3, omega-3 fatty acids; Tx, treatment; ND, no data.
comes. Furthermore, there was variability in the degree to which compliance was assessed. Similarly, there was variability in the rigor with which end points were defined and measured. Important covariates (e.g., use of antihypertensive agents, intensity of immunosuppression) often were not well described or applied uniformly, even when the study considered outcomes that may have been confounded by these factors.
Summary results were potentially underpowered because very few trials analyzed the statistical significance for net differences in effects. Most studies analyzed only differences between groups at various time points during the study.
Graft-Related Outcomes
Patient Survival. There were seven deaths out of a total of 830 kidney transplant patients, all of which were reported in three trials (8, 13, 14) . A total of four patients died with a functional graft within 1 yr of transplantation (one patient in the fish oil group and three patients in the placebo group) (8) . One patient died of myocardial infarction in the placebo group (13) . In a 9-mo RCT, two patients in the fish oil group died as a result of hemorrhagic shock from removal of native polycystic kidney and intestinal infarction (14) .
Graft Survival. A total of 10 RCT, with 291 patients in the fish oil group and 312 patients in the placebo or control group, described graft survival among kidney transplant recipients (Table 2) (9, (15) (16) (17) (18) (19) . However, most studies did not perform quantitative analysis of graft survival, underscoring the excellent overall results in kidney transplantation irrespective of fish oil supplementation. Fish oil supplementation began 3 d posttransplantation in eight of these 10 reports with a total of 228 and 234 subjects in the fish oil and control groups, respectively. The pooled RR of graft survival in those who received fish oil supplementation was 1.00 (95% CI 0.96 to 1.05). There was no statistical heterogeneity among studies (Figure 2) .
In two studies (16, 18) , fish oil was begun at 16 wk and Ͼ1 yr posttransplantation. Thus, the enrolled patients would be expected to have relatively stable renal function compared with the studies in which treatment began within 3 d after transplantation. No benefit from fish oil treatment was observed in either study.
Rejection Episodes. Acute rejection episodes were described at varying time points in a total of 11 trials, including 297 patients in the fish oil group and 282 patients in the placebo or control group (8,13-17,20 -23) . The studies all were of low or intermediate quality. Five of the 11 trials reported that rejection was verified by a biopsy. In all but two studies (published in three papers [16, 22, 23] ), treatment had been initiated within 3 d after transplantation.
One trial reported only total episodes of rejection according to treatment (rather than the proportion of patients who had a rejection episode), noting a statistically significant reduction in the total number of rejection episodes in the fish oil group (13). However, it was not possible to determine whether these differences could have been accounted for by multiple episodes of rejection in a small number of patients (or even a single patient). The authors described six episodes of rejection in the fish oil group compared with 10 in the control group during the first month. In the second and third months, there was only one episode in the fish oil group compared with nine in the control group (P ϭ 0.016). In months 4 through 6, there were no rejection episodes in either group. Between months 6 and 12, there was one rejection episode in each group. Thus, during the year after transplantation, the total number of acute rejection episodes was significantly lower in the fish oil group than in the controls (eight versus 20; P ϭ 0.029). These results did not translate into statistically significant improved graft survival at 1 yr (97 versus 84%; P ϭ 0.097).
The other eight RCT (in which treatment was started within 3 d posttransplantation) described the proportion of patients with at least one rejection episode. To allow for clinically meaningful comparisons across studies, we defined rejection episodes as being "early" (within the first 6 mo of transplantation) or "late" (after 6 mo). The results for early and late rejection were combined using a random-effects model, which showed no significant benefit at any time point examined (Table 3) . Results for two studies that reported episodes between 2 to 9 and 3 to 12 mo were not combined because the time points reported combined early and late episodes together (8, 14) . The combined RR of an episode in those who received fish oil was 0.91 (95% CI 0.75 to 1.11) in four studies, with a total of 224 subjects, that reported the longest follow-up (i.e., 1 yr; Figure 3 ). There was no significant heterogeneity among the studies. In two studies published in three papers (16, 22, 23) , supplementation was begun at 16 wk and an average of 25 mo posttransplantation. No significant differences in acute rejection episodes were found in either study.
Renal Function. Eleven RCT (Table 4 ) in 14 publications reported the effects of fish oil on GFR. No consistent benefit was observed in patients who were treated shortly after transplantation or those who had stable renal function and in whom treatment was started several months after transplantation, although there were exceptions. The magnitude of benefit suggested in trials with positive findings was modest and did not translate into improved graft survival with up to 1 yr of follow-up (13, 17, 19, 24) .
Cardiovascular Disease-Related Outcomes
A modest, consistent benefit was found only for triglyceride levels among kidney transplant recipients. Specifically, nine Figure 2 . Random-effects model meta-analysis of graft survival in RCT in kidney transplant patients. Each study is shown by a risk ratio (RR) estimate along with whiskers corresponding to its 95% confidence interval (CI). RCT (with a total of 200 and 199 patients in the fish oil and control groups, respectively) included triglycerides as an outcome (9, 14, 15, (17) (18) (19) 22, 23, 25, 26) . Although there were exceptions, in aggregate, the data support a benefit of fish oil in lowering serum triglyceride concentrations. One study that compared fish oil supplementation with lovastatin found the former to be more effective in reducing triglycerides (26) . Little or no effect was found for a variety of other cardiovascular risk factors and markers, such as total cholesterol, HDL, LDL, BP, and development of diabetes.
Effects of Fish Oil Supplementation in Subsets of Patients
Two trials (with a total of 53 patients in the fish oil group and 64 patients in the coconut oil group) from the same center described outcomes in patients with and without an episode of rejection (20, 21) . In one of these reports, patients who were randomized to the fish oil group demonstrated a significantly better recovery of renal function after an episode of histologically confirmed rejection (20) . The authors concluded that fish oil favorably influenced renal function in the recovery phase after a rejection episode.
In an earlier report, the authors analyzed a subset of patients without a rejection episode during the course of study (21) . Patients who received fish oil had a significantly higher filtration fraction, a significantly lower effective renal plasma flow (164 versus 262 ml/min per 1.73 m 2 ), and a significantly better response of the GFR after amino acid infusion (15.3 versus 10.6%).
All studies evaluated patients who received supplementation after transplantation. Figure 4 depicts the net difference in GFR and 95% CI across studies in kidney transplant recipients (8, 13, (15) (16) (17) 20, 21, 24, 27, 28) . Higher values suggest better renal function in those who received fish oil. CI could not be calculated for four studies in which the SD was not reported (13, 20, 21, 24) . Nevertheless, the data do not support a clear relationship between the time in which the supplement began and the treatment effect. However, the plotted data points represent the longest follow-up values considered in each report. Thus, it is possible that there may be differences in benefit related to the timing of supplementation at earlier time intervals after transplantation.
Effects on Immunosuppressive Agents and Related Drugs
No study provided a detailed evaluation of the interaction between fish oil and the various immunosuppressive drugs, except for dosing of CsA. The available data suggest that fish oil does not cause a clinically important interaction with CsA. No significant changes in total doses of CsA or trough levels were observed. However, the most detailed single study (14) that evaluated CsA pharmacokinetics in the presence of fish oil found that the area under the curve was higher in patients who received fish oil, and they had less variance in the time to peak levels. These differences did not achieve statistical significance. The authors concluded that this pattern provided evidence for better CsA absorption and metabolism in kidney transplant patients who receive fish oil.
Discussion
No consistent benefits were evident with omega-3 fatty acid supplementation on any outcome evaluated in kidney transplantation, with the exception of a modest reduction in triglyceride levels. The benefit on triglycerides is consistent with the effects of omega-3 fatty acids in the nontransplant setting (29) .
Limited data with inconclusive results were also found for other types of transplantation (www.AHRQ.gov). Among the five nonrenal transplant studies that were found (three on heart transplantation, one on liver transplantation, and one on bone marrow transplantation), the only potentially important clinical benefit reported was a reduction in acute colonic graft versus host disease and improved survival in a small RCT in bone marrow transplantation (30, 31) . However, there have been no additional studies to confirm these observations, raising concern as to whether the authors or other groups may not have been able to reproduce these results.
The main limitation of this systematic review relates to the quantity and quality of the available evidence and its applicability to contemporary transplantation procedures. Varied inclusion criteria, outcome measures, type and source of omega-3 fatty acids, assessment of compliance, and insufficient reporting limited detailed comparisons among studies with positive and negative findings, which may have permitted a better understanding of the heterogeneous results, especially for renal function.
All studies used fish oil as the source of omega-3 fatty acids. Thus, this report cannot address the effects of supplementation with ALA. Furthermore, there were insufficient data to determine the relationship between the background diet and the optimal ratio of omega-3 and omega-6 fatty acids on the outcomes of interest. All studies began omega-3 fatty acids after transplantation. Because it may take up to 3 wk for supplementation to have an effect on the production of various cytokines, it is possible that different results would be observed if supplementation had been started before transplantation.
Some trials found a benefit of fish oil supplementation on renal function (15, 17, 19, 24) . This suggests that fish oil could possibly benefit a subset of patients. However, no clear patient-or transplant-related characteristics emerged from careful comparisons of the RCT. Furthermore, whether the magnitude of the observed changes would translate into clinically important outcomes (e.g., improved graft survival) is uncertain, especially because the study durations were generally 1 yr or less. Two case reports suggested that fish oil improves proteinuria in patients who developed recurrent IgA nephropathy (32, 33) . The observation is potentially important because some studies have found a benefit from fish oil supplementation in IgA nephropathy in the nontransplant setting (34, 35) . Thus, further studies in transplant recipients with IgA nephropathy may be warranted.
The applicability of the results to contemporary transplantation procedures is unclear because most of the studies were performed Ͼ5 yr ago, with some more than a decade old. The technology for transplantation procedures continues to improve, with a wider choice of immunosuppressive agents and a better understanding of how to use them and the means to address the known complications of transplantation, including some of the important outcomes (e.g., hyperlipidemia and hypertension) for which the benefits of fish oil supplementation had been anticipated. A draft report (36) of a study in kidney transplantation using contemporary protocols suggested a possible benefit in achieving complete steroid withdrawal, but the precise contribution of the ALA supplements in achieving this objective is unclear (Dr. Wesley Alexander, University of Cincinnati Medical Center, Cincinnati, Ohio, personal communication, April 23, 2004 ). Furthermore, the lack of a control group makes the interpretation of this unpublished report more problematic.
The available data do not demonstrate a consistent, clinically important benefit of fish oil supplementation in kidney transplantation. Future research with omega-3 fatty acids might focus on understanding the factors associated with improvement in renal function with fish oil or ALA. There are new, more concentrated forms of EPA and DHA as well as fungal forms enriched in a specific omega-3 fatty acid. The possibility of factors associated with improvement in renal function, when these new forms of EPA and DHA are used, should also be investigated. Long-term follow-up studies should be conducted to determine whether any of the observed benefits were durable or translated into other improved outcomes. In addition, studies should be considered to determine whether fish oil supplementation might be beneficial in the treatment or prevention of IgA nephropathy after transplantation.
